IBA Molecular, Piramal Imaging sign agreement for 18F-Florbetaben distribution
IBA Molecular will manufacture and distribute 18F-Florbetaben, an imaging agent from Piramal Imaging, under terms of an agreement reached between the two companies.
Dulles, Va.-based IBA Molecular will distribute the agent, which is currently in development for use with PET imaging for the detection of beta-amyloid plaques in the brain, in the European and U.S. markets.
Piramal recently acquired the intellectual property, worldwide development, marketing and distribution rights of the lead compound 18F-Florbetaben to form the Piramal Imaging subsidiary.
Dulles, Va.-based IBA Molecular will distribute the agent, which is currently in development for use with PET imaging for the detection of beta-amyloid plaques in the brain, in the European and U.S. markets.
Piramal recently acquired the intellectual property, worldwide development, marketing and distribution rights of the lead compound 18F-Florbetaben to form the Piramal Imaging subsidiary.
Evan Godt, Writer
Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.